Recent Updates
Recently added Catalysts
NMRA Negative Sentiment Score: 25/100

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

Key Takeaway: Neumora Therapeutics, Inc. is facing a class action lawsuit led by the Portnoy Law Firm, informing investors of their legal rights and options to recover losses from investments made since September 15, 2023. The lawsuit claims that Neumora misled investors by modifying key trial criteria and failing to disclose critical information regarding their developmental programs. The deadline for investors to file a lead plaintiff motion is April 7, 2025. The firm is offering complimentary evaluations to discuss potential claims.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors have the opportunity to recover losses through a class action lawsuit, indicating significant investor dissatisfaction.
  • The complaint alleges that Neumora provided materially false or misleading statements regarding trial data and outcomes.
  • Concerns over insufficient data in Phase Two trials may undermine investor confidence in Neumora's clinical programs.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, April 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA) investors of a class action representing investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commencing on or about September 15, 2023. Neumora investors have until April 7, 2025 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint alleges that during the class period, Defendants made materially false or misleading statements and failed to disclose key information. Specifically, Neumora altered BlackThorn’s original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) in an effort to justify proceeding with its Phase Three Program and demonstrate that Navacaprant, its flagship therapeutic candidate, provided statistically significant improvement in treating MDD. Additionally, the company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD. Furthermore, the Phase Two trials lacked sufficient data—particularly regarding patient population size and the male-to-female ratio—making it difficult to accurately predict the outcomes of the KOASTAL-1 study.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can Neumora investors recover their losses?

Investors can contact the Portnoy Law Firm for a complimentary evaluation and explore options to recover losses.

What is the deadline for filing a lead plaintiff motion?

Investors have until April 7, 2025, to submit a lead plaintiff motion.

What allegations are made against Neumora Therapeutics?

The complaint alleges Neumora made misleading statements and altered trial criteria.

Who can investors contact for legal support?

Investors can reach attorney Lesley F. Portnoy at 310-692-8883 or via email.

What should investors do to join the class action?

Investors can visit the Portnoy Law Firm’s website to submit their transaction information.

Last updated: Apr 7, 2025